Glycotope GmbH

Booth number 4617-02

www.glycotope.com

Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.

About us

Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. We combine expertise in glycobiology and know-how in antibody development to advance first-in-class antibody-based therapeutics for (immuno)-oncology.

Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Targeting these specific antigens enables broad indication range, long-term treatment potential and reduced on-target/off tumor toxicity, which is key for highly potent therapies. Based on this unrivalled tumor-specificity, our antibodies are highly suitable for a multi-function platform approach with independent modes of action to provide a tailored therapy format for as many patients as possible.

Address
Glycotope GmbH
Robert-Roessle-Str. 10
13125 Berlin
Germany

Phone: +49 30 9489 2600
Internet: www.glycotope.com

Products and Services

Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.

GT-00A which is developed in multiple different formats, including an IL-15-based immune-cytokine (internal development).

GT-001 is a humanized IgG1 mAb with unrivaled fine-specificity, specifically targeting the tumor-associated Lewis Y (LeY, CD174) carbohydrate antigen without cross-reactivity to related carbohydrates expressed on blood cells.

GT-002 is an IgG1 mAb targeting LYPD3 (C4.4A) with increased tumor-specificity. LYPD3 is expressed in various cancer indications with high medical need, including squamous cell carcinoma of the head and neck (HNSCC). Upon binding to LYPD3, the antibody is effectively internalized.

Click here if you notice an image that violates copyright or privacy rights.

Get in contact
OK

We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection